Research programme: 1,3-beta-glucan synthase inhibitors - Daiichi Sankyo

Drug Profile

Research programme: 1,3-beta-glucan synthase inhibitors - Daiichi Sankyo

Alternative Names: Arborcandin C

Latest Information Update: 13 May 2008

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Class Cyclic peptides
  • Mechanism of Action Cell wall inhibitors; Glucan synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Mycoses

Most Recent Events

  • 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
  • 12 May 2003 Preclinical trials in Mycoses in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top